Sees FY25 adjusted EBITDA $41M. The company said, “We have not provided forward-looking guidance for net loss, the most directly comparable GAAP measure to Adjusted EBITDA, and therefore have not reconciled guidance for Adjusted EBITDA to net loss, because there are items that may impact net loss, including stock-based compensation, that are not within our control or cannot be reasonably forecasted.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst announces strategic partnership with Microsoft
- Health Catalyst price target lowered to $6.50 from $7 at Citi
- Health Catalyst price target lowered to $5 from $7 at KeyBanc
- Health Catalyst downgraded to In Line from Outperform at Evercore ISI
- Health Catalyst: A Strategic Buy Amidst Promising Growth and Platform Potential